Current stage-Stage II Posts on Medivizor
Navigation Menu

Current stage-Stage II Posts on Medivizor

Evaluating the long-term effectiveness and safety of abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Evaluating the long-term effectiveness and safety of abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Posted by on Jul 2, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the follow-up results of abemaciclib (Verzenio) plus endocrine (hormonal) therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive, and high-risk early breast cancer (BC). The data found that with a 4-year follow-up, adjuvant abemaciclib continued to show improvement in reducing the...

Read More

Evaluating the impact of fertility preservation on breast cancer and pregnancy outcomes in young women with breast cancer.

Evaluating the impact of fertility preservation on breast cancer and pregnancy outcomes in young women with breast cancer.

Posted by on Mar 15, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the impact of fertility preservation with ovarian stimulation on breast cancer and pregnancy outcomes in young women with breast cancer (BC). The data showed that fertility preservation was safe and did impact BC outcomes. Some background Breast cancer (BC) is one of the most common cancers affecting women...

Read More

Evaluating the role of radiotherapy in HER2+ early-stage breast cancer after breast-conserving surgery

Evaluating the role of radiotherapy in HER2+ early-stage breast cancer after breast-conserving surgery

Posted by on Mar 5, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the effectiveness of radiotherapy (RT) in patients with HER2+ early-stage breast cancer (BC) after breast-conserving surgery (BCS). The study found that RT improved the survival rates of these patients, especially for those high-risk. Some background BC is categorized based on the absence or...

Read More

Comparing the frequency and severity of nerve disease with eribulin versus paclitaxel before surgery in women with breast cancer

Comparing the frequency and severity of nerve disease with eribulin versus paclitaxel before surgery in women with breast cancer

Posted by on Jan 15, 2023 in Breast cancer | 0 comments

In a nutshell The study compared the frequency and severity of neuropathy (nerve damage) eribulin (Halaven) with paclitaxel (Taxol) given before surgery in women with operable breast cancer (BC). The study found that the frequency and severity of neuropathy were reduced in patients who received eribulin than in patients who received...

Read More

Evaluating the effectiveness of transanal endoscopic microsurgery for the treatment of early rectal cancer in patients over 60 years old with high surgical risk.

Evaluating the effectiveness of transanal endoscopic microsurgery for the treatment of early rectal cancer in patients over 60 years old with high surgical risk.

Posted by on Jan 3, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of transanal endoscopic microsurgery (TEM) for the treatment of early rectal cancer (RC) in patients over 60 years old with high surgical risk. The data showed that TEM is a reliable and effective treatment option in high-risk patients over 60 years old. Some background Rectal cancer (RC) is one of...

Read More

Evaluating the effectiveness and safety of adding oxaliplatin (3 months vs 6 months) to 6 months of fluoropyrimidine after surgery in patients with stage II or III colon cancer.

Evaluating the effectiveness and safety of adding oxaliplatin (3 months vs 6 months) to 6 months of fluoropyrimidine after surgery in patients with stage II or III colon cancer.

Posted by on Dec 31, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding oxaliplatin (Eloxatin; 3 months vs 6 months) to 6 months of fluoropyrimidine therapy such as 5-Fluorouracil (Adrucil) or capecitabine (Xeloda) as adjuvant (treatment after surgery) treatment in patients with stage II or III colon cancer. The data showed that adding 3 months of...

Read More

Adding pembrolizumab before and after surgery for early triple-negative breast cancer

Adding pembrolizumab before and after surgery for early triple-negative breast cancer

Posted by on Jun 30, 2022 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate pembrolizumab (Keytruda) before and after surgery in patients with early triple-negative breast cancer (TNBC).  This study concluded that the addition of pembrolizumab to chemotherapy before surgery and after surgery for TNBC improved the survival without complications from TNBC in these...

Read More

Aromatase inhibitors versus tamoxifen for premenopausal women with hormone positive early-stage breast cancer treated with ovarian suppression.

Aromatase inhibitors versus tamoxifen for premenopausal women with hormone positive early-stage breast cancer treated with ovarian suppression.

Posted by on Jun 26, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of aromatase inhibitors (AIs) versus tamoxifen (Nolvadex) for the treatment of premenopausal patients with estrogen receptor-positive (ER+) early-stage breast cancer (BC) treated with ovarian suppression. The data showed that AIs significantly reduced the risk of BC recurrence compared...

Read More

Evaluating the long-term effectiveness and safety of adding carboplatin with or without veliparib to standard chemotherapy given before surgery in patients with triple‑negative breast cancer.

Evaluating the long-term effectiveness and safety of adding carboplatin with or without veliparib to standard chemotherapy given before surgery in patients with triple‑negative breast cancer.

Posted by on May 8, 2022 in Breast cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of adding carboplatin (Paraplatin) with or without veliparib (ABT-888) to standard chemotherapy given before surgery (neoadjuvant chemotherapy; NACT) in patients with early-stage triple-negative breast cancer (TNBC). The data showed that the addition of carboplatin to standard NACT...

Read More

Comparing effectiveness of intraoperative radiotherapy and whole breast irradiation in patients with early breast cancer

Comparing effectiveness of intraoperative radiotherapy and whole breast irradiation in patients with early breast cancer

Posted by on Apr 26, 2022 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the oncological effectiveness of intraoperative radiotherapy (IORT) and whole breast irradiation (WBI) for patients with early breast cancer (BC).  This study concluded that there was a high oncological effectiveness for both groups of patients.  Some background Intraoperative...

Read More

Extended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.

Extended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.

Posted by on Oct 24, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of extended therapy with letrozole (LET; Femara) for 5 years versus the standard therapy of 2-3 years for the treatment of postmenopausal women with early-stage breast cancer (BC). The data showed that extended treatment with LET for 5 years significantly improved the survival outcomes...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2023 Medivizor